BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

February 6, 2024

https://www.globenewswire.com/news-release/2024/02/06/2824137/0/en/BioXcel-Therapeutics-Announces-Completion-of-Patient-Enrollment-in-Safety-Portion-of-Investigator-Sponsored-Phase-2-Relapsed-Pancreatic-Cancer-Trial-of-BXCL701-in-Combination-with-.html

Human proof of concept portion of the trial expected to begin in H1 2024; led by Georgetown Lombardi Comprehensive Cancer Center

BXCL701 in combination with checkpoint inhibitor in preclinical studies demonstrated encouraging results in pancreatic cancer

Read more at globenewswire.com

Related news for (BTAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.